Earnings Feed
Start Free
CAPRICOR THERAPEUTICS, INC.·4

Apr 1, 8:00 PM ET

Sabar Karimah Es 4

Research Summary

AI-generated summary

Updated

Capricor (CAPR) Director Sabar Karimah Es Exercises Options, Sells Shares

What Happened

  • Director Sabar Karimah Es exercised a total of 115,000 option shares (61,265 on 2026-03-31 and 53,735 on 2026-04-01) at $4.86 per share and then sold those same shares in the open market. The sales generated gross proceeds of approximately $3,515,468; the aggregate exercise cost was $558,900, leaving about $2,956,568 before taxes and fees. The sales were executed under a pre-established 10b5-1 trading plan.

Key Details

  • Transaction dates and prices:
    • 2026-03-31: Exercised 61,265 shares @ $4.86 (cost $297,748); sold 61,265 shares @ weighted avg $30.17 (gross $1,848,243). (Sale prices ranged $30.00–$30.46.)
    • 2026-04-01: Exercised 53,735 shares @ $4.86 (cost $261,152); sold 53,735 shares @ weighted avg $31.03 (gross $1,667,225). (Sale prices ranged $30.28–$31.39.)
  • Total exercised: 115,000 shares; total gross sale proceeds ≈ $3.52M; total exercise cost ≈ $558.9k; proceeds minus exercise cost ≈ $2.96M (pre-tax, pre-fees).
  • Shares owned after the transactions are not specified in the provided filing.
  • Footnotes of note:
    • Sales were made pursuant to a 10b5-1 trading plan adopted by the reporting person in December 2025.
    • Weighted-average sale prices and price ranges are provided in the filing (see above).
    • Vesting: original award vested 25% on Aug 1, 2022, with the remainder vesting monthly thereafter (1/36 per month).
    • The filing shows the derivative instruments were converted/exercised (reported as dispositions of the derivative and acquisitions of common stock).
  • Filing timeliness: Form 4 was filed 2026-04-01 for transactions on 2026-03-31 and 2026-04-01; this appears timely under Form 4 reporting rules.

Context

  • This was an option exercise followed by immediate sale of the acquired shares (commonly a cashless exercise pattern). The use of a 10b5-1 plan indicates the sales were pre-arranged, which is common for officers/directors to avoid trading-rule timing issues. These transactions are factual disclosures and do not, by themselves, indicate the director’s ongoing view of the company.